Dr. Reddy's Laboratories unveils Abiraterone Acetate Tablets USP in 250 mg in the US
22 June 2020 -

Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE: 500124) (NSE:DRREDDY) (NYSE:RDY) reported on Friday the availability of Abiraterone Acetate Tablets USP in the US market in 250 mg tablets in bottle count sizes of 120.

The company added that Abiraterone Acetate Tablets USP, 250 mg is the therapeutic equivalent generic version of Zytiga (abiraterone acetate), which has been approved by the US Food and Drug Administration (USFDA).

For the most recent 12 months ending in March 2020, Zytiga brand and generic market had US sales of about USD454m MAT, according to IQVIA Health.

Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer, added the company.